Gain Long Term Debt Total vs Capital Surpluse Analysis

GANX Stock

USD 2.96 0.03 1.02%

Gain Therapeutics financial indicator trend analysis is much more than just examining Gain Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Gain Therapeutics is a good investment. Please check the relationship between Gain Therapeutics Long Term Debt Total and its Capital Surpluse accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.

Long Term Debt Total vs Capital Surpluse

Long Term Debt Total vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Gain Therapeutics Long Term Debt Total account and Capital Surpluse. At this time, the significance of the direction appears to have totally related.

The correlation between Gain Therapeutics' Long Term Debt Total and Capital Surpluse is 1.0. Overlapping area represents the amount of variation of Long Term Debt Total that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Gain Therapeutics, assuming nothing else is changed. The correlation between historical values of Gain Therapeutics' Long Term Debt Total and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt Total of Gain Therapeutics are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Long Term Debt Total i.e., Gain Therapeutics' Long Term Debt Total and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Long Term Debt Total

Capital Surpluse

Most indicators from Gain Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Gain Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.At this time, Gain Therapeutics' Tax Provision is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 11.3 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 3 M in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	15.5K	64.2K	78.1K	82.0K
Total Operating Expenses	14.0M	17.9M	22.2M	11.2M

Reconciled Depreciation Total Operating Expenses

Gain Therapeutics fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total
Other Current Liab		0.99	0.77	0.87	-0.89	0.94	0.85	0.79	0.81	0.96	0.98	0.83	0.97	0.03	0.85	0.85	0.8	0.86	0.35	-0.62	0.64	0.83	0.68	0.83	0.93	0.83
Total Current Liabilities	0.99		0.74	0.82	-0.91	0.95	0.86	0.82	0.84	0.92	0.96	0.77	0.96	-0.03	0.79	0.83	0.73	0.81	0.42	-0.56	0.58	0.77	0.65	0.77	0.91	0.81
Other Liab	0.77	0.74		0.92	-0.64	0.65	0.86	0.63	0.82	0.78	0.82	0.93	0.79	0.53	0.92	0.92	0.92	0.92	0.21	-0.9	0.91	0.6	0.8	0.93	0.8	0.93
Net Tangible Assets	0.87	0.82	0.92		-0.72	0.71	0.82	0.67	0.68	0.93	0.93	0.99	0.91	0.48	0.98	0.9	0.97	0.95	0.22	-0.92	0.93	0.7	0.73	0.99	0.88	0.9
Retained Earnings	-0.89	-0.91	-0.64	-0.72		-0.82	-0.71	-0.97	-0.76	-0.84	-0.89	-0.67	-0.9	0.2	-0.71	-0.71	-0.65	-0.72	-0.71	0.49	-0.53	-0.67	-0.41	-0.69	-0.95	-0.71
Accounts Payable	0.94	0.95	0.65	0.71	-0.82		0.87	0.7	0.82	0.84	0.86	0.68	0.85	-0.1	0.71	0.82	0.65	0.78	0.26	-0.42	0.45	0.85	0.73	0.67	0.82	0.79
Other Assets	0.85	0.86	0.86	0.82	-0.71	0.87		0.67	0.83	0.76	0.83	0.82	0.81	0.33	0.82	0.96	0.78	0.88	0.24	-0.7	0.72	0.66	0.9	0.8	0.79	0.96
Net Receivables	0.79	0.82	0.63	0.67	-0.97	0.7	0.67		0.71	0.73	0.81	0.63	0.83	-0.14	0.66	0.67	0.61	0.66	0.83	-0.52	0.55	0.49	0.34	0.65	0.91	0.68
Common Stock Shares Outstanding	0.81	0.84	0.82	0.68	-0.76	0.82	0.83	0.71		0.7	0.78	0.66	0.75	0.02	0.68	0.79	0.63	0.73	0.37	-0.51	0.54	0.62	0.68	0.66	0.76	0.79
Other Current Assets	0.96	0.92	0.78	0.93	-0.84	0.84	0.76	0.73	0.7		0.98	0.9	0.97	0.14	0.91	0.83	0.88	0.89	0.27	-0.72	0.73	0.85	0.62	0.9	0.93	0.8
Other Stockholder Equity	0.98	0.96	0.82	0.93	-0.89	0.86	0.83	0.81	0.78	0.98		0.89	1.0	0.14	0.89	0.85	0.85	0.88	0.39	-0.72	0.74	0.76	0.64	0.88	0.95	0.84
Total Current Assets	0.83	0.77	0.93	0.99	-0.67	0.68	0.82	0.63	0.66	0.9	0.89		0.86	0.53	1.0	0.92	1.0	0.98	0.16	-0.94	0.95	0.73	0.77	1.0	0.86	0.92
Common Stock	0.97	0.96	0.79	0.91	-0.9	0.85	0.81	0.83	0.75	0.97	1.0	0.86		0.11	0.87	0.82	0.83	0.85	0.44	-0.71	0.72	0.73	0.59	0.86	0.95	0.81
Property Plant Equipment	0.03	-0.03	0.53	0.48	0.2	-0.1	0.33	-0.14	0.02	0.14	0.14	0.53	0.11		0.48	0.43	0.53	0.44	-0.34	-0.73	0.71	-0.02	0.53	0.51	0.07	0.46
Total Assets	0.85	0.79	0.92	0.98	-0.71	0.71	0.82	0.66	0.68	0.91	0.89	1.0	0.87	0.48		0.93	1.0	0.99	0.19	-0.92	0.93	0.76	0.77	1.0	0.89	0.93
Short Long Term Debt Total	0.85	0.83	0.92	0.9	-0.71	0.82	0.96	0.67	0.79	0.83	0.85	0.92	0.82	0.43	0.93		0.91	0.98	0.19	-0.82	0.84	0.75	0.91	0.92	0.85	1.0
Total Stockholder Equity	0.8	0.73	0.92	0.97	-0.65	0.65	0.78	0.61	0.63	0.88	0.85	1.0	0.83	0.53	1.0	0.91		0.98	0.14	-0.94	0.95	0.73	0.76	1.0	0.86	0.91
Property Plant And Equipment Net	0.86	0.81	0.92	0.95	-0.72	0.78	0.88	0.66	0.73	0.89	0.88	0.98	0.85	0.44	0.99	0.98	0.98		0.16	-0.87	0.89	0.81	0.85	0.98	0.89	0.96
Current Deferred Revenue	0.35	0.42	0.21	0.22	-0.71	0.26	0.24	0.83	0.37	0.27	0.39	0.16	0.44	-0.34	0.19	0.19	0.14	0.16		-0.16	0.18	-0.03	-0.17	0.2	0.54	0.23
Net Debt	-0.62	-0.56	-0.9	-0.92	0.49	-0.42	-0.7	-0.52	-0.51	-0.72	-0.72	-0.94	-0.71	-0.73	-0.92	-0.82	-0.94	-0.87	-0.16		-1.0	-0.47	-0.67	-0.94	-0.72	-0.84
Cash	0.64	0.58	0.91	0.93	-0.53	0.45	0.72	0.55	0.54	0.73	0.74	0.95	0.72	0.71	0.93	0.84	0.95	0.89	0.18	-1.0		0.49	0.69	0.95	0.75	0.86
Non Current Assets Total	0.83	0.77	0.6	0.7	-0.67	0.85	0.66	0.49	0.62	0.85	0.76	0.73	0.73	-0.02	0.76	0.75	0.73	0.81	-0.03	-0.47	0.49		0.68	0.73	0.76	0.69
Non Currrent Assets Other	0.68	0.65	0.8	0.73	-0.41	0.73	0.9	0.34	0.68	0.62	0.64	0.77	0.59	0.53	0.77	0.91	0.76	0.85	-0.17	-0.67	0.69	0.68		0.75	0.58	0.9
Cash And Short Term Investments	0.83	0.77	0.93	0.99	-0.69	0.67	0.8	0.65	0.66	0.9	0.88	1.0	0.86	0.51	1.0	0.92	1.0	0.98	0.2	-0.94	0.95	0.73	0.75		0.88	0.92
Common Stock Total Equity	0.93	0.91	0.8	0.88	-0.95	0.82	0.79	0.91	0.76	0.93	0.95	0.86	0.95	0.07	0.89	0.85	0.86	0.89	0.54	-0.72	0.75	0.76	0.58	0.88		0.84
Non Current Liabilities Total	0.83	0.81	0.93	0.9	-0.71	0.79	0.96	0.68	0.79	0.8	0.84	0.92	0.81	0.46	0.93	1.0	0.91	0.96	0.23	-0.84	0.86	0.69	0.9	0.92	0.84

Click cells to compare fundamentals

Gain Therapeutics Account Relationship Matchups

Gain Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	253.7K	768.5K	1.4M	2.1M	2.2M	1.3M
Total Current Liabilities	879.1K	2.1M	2.6M	4.1M	4.9M	2.8M
Other Liab	132.2K	171.6K	329.5K	157.6K	181.2K	179.3K
Net Tangible Assets	(450.0K)	6.2M	34.6M	18.7M	21.5M	12.8M
Retained Earnings	(3.5M)	(7.0M)	(20.9M)	(38.5M)	(60.8M)	(57.7M)
Accounts Payable	154.4K	961.5K	560.5K	1.6M	1.3M	874.7K
Other Assets	11.4K	63.8K	53.4K	48.3K	55.6K	41.4K
Net Receivables	44.9K	66.6K	113.6K	103.9K	242.6K	254.7K
Other Current Assets	49.8K	71.0K	727.8K	848.9K	741.6K	456.7K
Other Stockholder Equity	3.1M	13.4M	55.8M	57.4M	73.1M	37.2M
Total Current Assets	429.5K	9.0M	37.7M	21.1M	17.8M	15.9M
Property Plant Equipment	219.3K	552.7K	1.0M	144.4K	166.0K	157.7K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Gain Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Gain Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Gain Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Gain Therapeutics Stock:

How To Invest In Gain

Details

Is Gain Stock a good investment?

Details

What is Gain Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Gain Stock analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	CEOs Directory Screen CEOs from public companies around the world
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm

Is Gain Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gain Therapeutics. If investors know Gain will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gain Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.71)

Revenue Per Share

0.004

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.65)

Return On Equity

(1.42)

The market value of Gain Therapeutics is measured differently than its book value, which is the value of Gain that is recorded on the company's balance sheet. Investors also form their own opinion of Gain Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gain Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gain Therapeutics' market value can be influenced by many factors that don't directly affect Gain Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Gain Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gain Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gain Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Gain Long Term Debt Total vs Capital Surpluse Analysis

Long Term Debt Total vs Capital Surpluse

Long Term Debt Total vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Long Term Debt Total

Capital Surpluse

Gain Therapeutics fundamental ratios Correlations

Gain Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Gain Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Gain Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Other Stockholder Equity
Total Assets	+ 1.0	Total Current Assets
Total Stockholder Equity	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Current Assets
Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets

Cash	- 1.0	Net Debt
Net Receivables	- 0.97	Retained Earnings
Common Stock Total Equity	- 0.95	Retained Earnings
Cash And Short Term Investments	- 0.94	Net Debt
Net Debt	- 0.94	Total Stockholder Equity
Net Debt	- 0.94	Total Current Assets